Drug development against tuberculosis: Past, present and future

Infection with Mycobacterium tuberculosis (MTB) was detected as early as 5000 years ago with confirmation, which is a primeval enemy of the humanoid race. It residues a main cause of morbidity and mortality in poor low-income countries as well as in developing countries because of non-availability of reliable laboratory services. The present treatment for drug-resistant tuberculosis (TB) is lengthy, difficult, and connected with severe harmful side effects and reduced outcomes. Furthermore, the emergence of multi-drug resistant tuberculosis eruptions is hampering efforts to control and manage tuberculosis. Also, the pipeline of possible new treatments has been fulfilled with several compounds in clinical trials or preclinical development with promising activities against sensitive and resistant MTB bacteria. An additional new chemical entity is also under development.